Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era

Dong Wook Kim; Shripad D. Banavali; Udomsak Bunworasate; Yeow Tee Goh; Peter Ganly; He Huang; Ian Irving; Saengsuree Jootar; Hyun Gyung Goh; Liang Piu Koh; Wei Li; Tomoki Naoe; Soo Chin Ng; Visalachy Purushotaman; Harryanto Reksodiputro; Lee Yung Shih; Jih Luh Tang; Arinobu Tojo; Jianmin Wang; Raymond Wong

doi:10.1016/j.leukres.2010.03.033

Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era

Dong Wook Kim^*
, Shripad D. Banavali
, Udomsak Bunworasate
, Yeow Tee Goh
, Peter Ganly
, He Huang
, Ian Irving
, Saengsuree Jootar
, Hyun Gyung Goh
, Liang Piu Koh
, Wei Li
, Tomoki Naoe
, Soo Chin Ng
, Visalachy Purushotaman
, Harryanto Reksodiputro
, Lee Yung Shih
, Jih Luh Tang
, Arinobu Tojo
, Jianmin Wang
, Raymond Wong

^*此作品的通信作者

醫學系

The Catholic University of Korea
Tata Memorial Hospital
Chulalongkorn University
Singapore General Hospital
Canterbury District Health Board
Zhejiang University
Queensland Health
Mahidol University
National University Cancer Institute
Jilin University
Nagoya University
Sime Darby Medical Center Subang Jaya
Ampang Hospital
University of Indonesia
National Taiwan University
The University of Tokyo
Naval Medical University
Chinese University of Hong Kong

研究成果: 期刊稿件 › 文章 › 同行評審

41 引文斯高帕斯（Scopus）

摘要

Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization.Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines.

原文	英語
頁（從 - 到）	1459-1471
頁數	13
期刊	Leukemia Research
卷	34
發行號	11
DOIs	https://doi.org/10.1016/j.leukres.2010.03.033
出版狀態	已出版 - 11 2010

UN SDG

此研究成果有助於以下永續發展目標

SDG3 健康與福祉

存取文件

10.1016/j.leukres.2010.03.033

其它文件與鏈接

Link to publication in Scopus

引用此

Kim, D. W., Banavali, S. D., Bunworasate, U., Goh, Y. T., Ganly, P., Huang, H., Irving, I., Jootar, S., Goh, H. G., Koh, L. P., Li, W., Naoe, T., Ng, S. C., Purushotaman, V., Reksodiputro, H., Shih, L. Y., Tang, J. L., Tojo, A., Wang, J., & Wong, R. (2010). Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era. Leukemia Research, 34(11), 1459-1471. https://doi.org/10.1016/j.leukres.2010.03.033

@article{613d631793b04c12baa169bd167cd78e,

title = "Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era",

abstract = "Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization.Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines.",

keywords = "Asia, CML, Clinical practice, Imatinib, Management, Survey, TKI",

author = "Kim, \{Dong Wook\} and Banavali, \{Shripad D.\} and Udomsak Bunworasate and Goh, \{Yeow Tee\} and Peter Ganly and He Huang and Ian Irving and Saengsuree Jootar and Goh, \{Hyun Gyung\} and Koh, \{Liang Piu\} and Wei Li and Tomoki Naoe and Ng, \{Soo Chin\} and Visalachy Purushotaman and Harryanto Reksodiputro and Shih, \{Lee Yung\} and Tang, \{Jih Luh\} and Arinobu Tojo and Jianmin Wang and Raymond Wong",

year = "2010",

month = nov,

doi = "10.1016/j.leukres.2010.03.033",

language = "英语",

volume = "34",

pages = "1459--1471",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "11",

}

Kim, DW, Banavali, SD, Bunworasate, U, Goh, YT, Ganly, P, Huang, H, Irving, I, Jootar, S, Goh, HG, Koh, LP, Li, W, Naoe, T, Ng, SC, Purushotaman, V, Reksodiputro, H, Shih, LY, Tang, JL, Tojo, A, Wang, J & Wong, R 2010, 'Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era', Leukemia Research, 卷 34, 編號 11, 頁 1459-1471. https://doi.org/10.1016/j.leukres.2010.03.033

TY - JOUR

T1 - Chronic myeloid leukemia in the Asia-Pacific region

T2 - Current practice, challenges and opportunities in the targeted therapy era

AU - Kim, Dong Wook

AU - Banavali, Shripad D.

AU - Bunworasate, Udomsak

AU - Goh, Yeow Tee

AU - Ganly, Peter

AU - Huang, He

AU - Irving, Ian

AU - Jootar, Saengsuree

AU - Goh, Hyun Gyung

AU - Koh, Liang Piu

AU - Li, Wei

AU - Naoe, Tomoki

AU - Ng, Soo Chin

AU - Purushotaman, Visalachy

AU - Reksodiputro, Harryanto

AU - Shih, Lee Yung

AU - Tang, Jih Luh

AU - Tojo, Arinobu

AU - Wang, Jianmin

AU - Wong, Raymond

PY - 2010/11

Y1 - 2010/11

N2 - Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization.Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines.

AB - Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization.Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines.

KW - Asia

KW - CML

KW - Clinical practice

KW - Imatinib

KW - Management

KW - Survey

KW - TKI

UR - https://www.scopus.com/pages/publications/77957018636

U2 - 10.1016/j.leukres.2010.03.033

DO - 10.1016/j.leukres.2010.03.033

M3 - 文章

C2 - 20430443

AN - SCOPUS:77957018636

SN - 0145-2126

VL - 34

SP - 1459

EP - 1471

JO - Leukemia Research

JF - Leukemia Research

IS - 11

ER -

Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era

摘要

UN SDG

存取文件

其它文件與鏈接

指紋

引用此